You are a clinical pharmacist employed by a commercial insurance company. You are tasked with determining whether to add tezepelumab to the insurance formulary. Which one of the following is most important to con- sider when determining whether tezepelumab should be added to the formulary? A. Tezepelumab has shown effectiveness in severe asthma regardless of phenotype. B. Anaphylaxis was not identified in clinical trials. C. Biomarker testing is not needed for initiation of therapy. D. Tezepelumab can be self-administered.
[Answered]: You are a clinical pharmacist employed by a…
Need help with your Respiratory & Gas Exchange case study or NCLEX preparation? Connect with a verified Nursing expert now.